What is the appropriate antiplatelet management prior to cataract surgery?

Antiplatelet Management Prior to Cataract Surgery

Continue all antiplatelet agents, including aspirin and P2Y12 inhibitors, throughout the perioperative period for cataract surgery. Cataract surgery is classified as a low bleeding-risk procedure, and the risk of thromboembolic events from discontinuing antiplatelet therapy far outweighs the minimal risk of sight-threatening hemorrhagic complications 1.

Evidence-Based Approach

The most recent and highest-quality guideline evidence from the American College of Chest Physicians (2022) provides clear direction: patients receiving antiplatelet drugs undergoing minor ophthalmologic procedures should continue their antiplatelet therapy 1. This applies to both aspirin and P2Y12 inhibitors. For patients on dual antiplatelet therapy (DAPT), you may continue aspirin and interrupt the P2Y12 inhibitor if absolutely necessary, though continuation of both is preferred for modern phacoemulsification with topical anesthesia 1.

Risk Stratification

Cataract surgery carries exceptionally low bleeding risk when performed with:

• Topical or intracameral anesthesia (preferred method)
• Clear corneal phacoemulsification technique
• Avoidance of sharp needle blocks

The 2025 meta-analysis of 65,196 patients confirms that aspirin continuation increases only subconjunctival hemorrhage risk (RR: 1.74), but does not increase risks of 2:

• Hyphema
• Retrobulbar hemorrhage
• Vitreous hemorrhage
• Posterior capsule rupture
• Vision loss

Specific Management by Antiplatelet Type

Aspirin Monotherapy

• Continue without interruption 1, 2
• No dose adjustment needed
• Safe even with therapeutic doses

P2Y12 Inhibitors (Clopidogrel, Ticagrelor, Prasugrel)

• Continue throughout surgery for routine cataract procedures 1
• If using peribulbar/retrobulbar sharp needle anesthesia (not recommended), consider stopping:
  • Clopidogrel: 5 days before
  • Ticagrelor: 3-5 days before
  • Prasugrel: 7 days before 3, 4

Dual Antiplatelet Therapy (DAPT)

• Continue both agents for topical/sub-Tenon's anesthesia 1
• Aspirin should never be stopped in patients with recent coronary stents 3
• Resume any interrupted P2Y12 inhibitor within 24 hours postoperatively 3

Critical Caveats

Anesthesia technique is the key determinant of bleeding risk, not the antiplatelet medication itself. The French guidelines specifically note that peribulbar anesthesia has been performed safely in large series of aspirin-treated patients, though data for P2Y12 inhibitors is limited 3. When possible, prefer topical or sub-Tenon's approaches over sharp needle techniques.

Never discontinue antiplatelet therapy without cardiology consultation in patients with 3:

• Coronary stents placed within 6-12 months
• Recent myocardial infarction (within 6 months)
• High thrombotic risk conditions

The risk of stent thrombosis or acute coronary syndrome from stopping antiplatelet therapy can be catastrophic (mortality risk), while cataract surgery bleeding complications are typically minor and self-limited.

Postoperative Management

• Resume any interrupted antiplatelet agents within 24 hours of surgery 4, 1
• No loading dose required for resumption 3
• Avoid NSAIDs perioperatively in patients on DAPT (increased bleeding risk) 3
• COX-2 inhibitors (coxibs) are acceptable alternatives 3

The evidence overwhelmingly supports continuation of antiplatelet therapy for modern cataract surgery, prioritizing patient safety from thrombotic events over the minimal risk of manageable surgical bleeding 1, 2, 5, 6, 7.